A phase 1 study in patients with advanced non-small cell lung cancer treated with stereotactic radiotherapy to the primary tumor combined with durvalumab and tremelimumab

Hanneke Kievit; Maartje Benthe Muntinghe-Wagenaar; Fred Ubbels; Robin Wijsman; Lucie Hijmering-Kappelle; Birgitta Hiddinga; Harry J. M.  Groen; Huib A.M. Kerstjens; A. J. van der Wekken; T. Jeroen Nicolaas Hiltermann

doi:10.1200/JCO.2022.40.16_suppl.e21121

A phase 1 study in patients with advanced non-small cell lung cancer treated with stereotactic radiotherapy to the primary tumor combined with durvalumab and tremelimumab

Hanneke Kievit, Maartje Benthe Muntinghe-Wagenaar, Fred Ubbels, Robin Wijsman, Lucie Hijmering-Kappelle, Birgitta Hiddinga, Harry J. M. Groen, Huib A.M. Kerstjens, A. J. van der Wekken, T. Jeroen Nicolaas Hiltermann

Onderzoeksoutput › Academic

Originele taal-2	English
Pagina's (van-tot)	e21121-e21121
Aantal pagina's	1
Tijdschrift	Journal of Clinical Oncology
Volume	40
Nummer van het tijdschrift	16_suppl
DOI's	https://doi.org/10.1200/JCO.2022.40.16_suppl.e21121
Status	Published - 1-jun.-2022
Evenement	ASCO Annual Meeting 2022 - Chicago, United States Duur: 3-jun.-2022 → 7-jun.-2022

Toegang tot document

10.1200/JCO.2022.40.16_suppl.e21121

Handle.net

Permanente koppeling

Citeer dit

Kievit, H., Muntinghe-Wagenaar, M. B., Ubbels, F., Wijsman, R., Hijmering-Kappelle, L., Hiddinga, B., Groen, H. J. M., Kerstjens, H. A. M., van der Wekken, A. J., & Hiltermann, T. J. N. (2022). A phase 1 study in patients with advanced non-small cell lung cancer treated with stereotactic radiotherapy to the primary tumor combined with durvalumab and tremelimumab. Journal of Clinical Oncology, 40(16_suppl), e21121-e21121. https://doi.org/10.1200/JCO.2022.40.16_suppl.e21121

@article{ac249cb6f9634861a74be9756ebcb504,

title = "A phase 1 study in patients with advanced non-small cell lung cancer treated with stereotactic radiotherapy to the primary tumor combined with durvalumab and tremelimumab",

author = "Hanneke Kievit and Muntinghe-Wagenaar, {Maartje Benthe} and Fred Ubbels and Robin Wijsman and Lucie Hijmering-Kappelle and Birgitta Hiddinga and Groen, {Harry J. M.} and Kerstjens, {Huib A.M.} and {van der Wekken}, {A. J.} and Hiltermann, {T. Jeroen Nicolaas}",

year = "2022",

month = jun,

day = "1",

doi = "10.1200/JCO.2022.40.16_suppl.e21121",

language = "English",

volume = "40",

pages = "e21121--e21121",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "AMER SOC CLINICAL ONCOLOGY",

number = "16_suppl",

note = "ASCO Annual Meeting 2022 ; Conference date: 03-06-2022 Through 07-06-2022",

}

Kievit, H , Muntinghe-Wagenaar, MB , Ubbels, F , Wijsman, R , Hijmering-Kappelle, L , Hiddinga, B , Groen, HJM , Kerstjens, HAM , van der Wekken, AJ & Hiltermann, TJN 2022, 'A phase 1 study in patients with advanced non-small cell lung cancer treated with stereotactic radiotherapy to the primary tumor combined with durvalumab and tremelimumab', Journal of Clinical Oncology, vol. 40, nr. 16_suppl, blz. e21121-e21121. https://doi.org/10.1200/JCO.2022.40.16_suppl.e21121

TY - JOUR

T1 - A phase 1 study in patients with advanced non-small cell lung cancer treated with stereotactic radiotherapy to the primary tumor combined with durvalumab and tremelimumab

AU - Kievit, Hanneke

AU - Muntinghe-Wagenaar, Maartje Benthe

AU - Ubbels, Fred

AU - Wijsman, Robin

AU - Hijmering-Kappelle, Lucie

AU - Hiddinga, Birgitta

AU - Groen, Harry J. M.

AU - Kerstjens, Huib A.M.

AU - van der Wekken, A. J.

AU - Hiltermann, T. Jeroen Nicolaas

PY - 2022/6/1

Y1 - 2022/6/1

U2 - 10.1200/JCO.2022.40.16_suppl.e21121

DO - 10.1200/JCO.2022.40.16_suppl.e21121

M3 - Meeting Abstract

SN - 0732-183X

VL - 40

SP - e21121-e21121

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 16_suppl

T2 - ASCO Annual Meeting 2022

Y2 - 3 June 2022 through 7 June 2022

ER -

Kievit H , Muntinghe-Wagenaar MB , Ubbels F , Wijsman R , Hijmering-Kappelle L , Hiddinga B et al. A phase 1 study in patients with advanced non-small cell lung cancer treated with stereotactic radiotherapy to the primary tumor combined with durvalumab and tremelimumab. Journal of Clinical Oncology. 2022 jun. 1;40(16_suppl):e21121-e21121. doi: 10.1200/JCO.2022.40.16_suppl.e21121